Liver impairment drug study completed: how golcadomide behaves

NCT ID NCT06535399

Completed Knowledge-focused Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study looked at how the drug golcadomide is processed in the body of people with moderate or severe liver impairment compared to healthy volunteers. 29 adults received a single dose, and researchers measured drug levels and safety. The goal is to understand if liver problems change how the drug works, which could guide future dosing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: golcadomide (BMS-986369)
What this could lead to: If successful, this study could help determine safe dosing of golcadomide for people with liver problems.
What could go wrong: This is a very early (Phase 1) study with only 29 participants, so results may not apply broadly. The drug may still have safety issues or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS HEPATIC IMPAIRMENT

Contacts and locations

Locations

Local Institution - 0001

Chandler, Arizona, 85225, United States
Local Institution - 0002

Orlando, Florida, 32809, United States
Texas Liver Institute

San Antonio, Texas, 78215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.